Search Results 191-200 of 11357 for ���������������������������:za33���24������ ������������������������ ������

  1. ZTE MRI for Visualization of Bone Cement, Breast Biopsy Markers - Mayo Clinic

    Rochester, Minnesota: 24-010877. NCT ID: NCT06873802. Sponsor Protocol Number: 24-010877. About this study. The purpose of this study is to demonstrate that ZTE ...

  2. Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States - Mayo Clinic

    Myocardial infarction, Unstable angina, transient ischemic events, or stroke within 24 weeks of screening. 3. Alcohol Use Disorder Identification Test ...

  3. To Assess the Effectiveness, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness, safety, tolerability, and PK of INCB000928 over a 24-week treatment period followed by a 52-week ...

  4. https://www.mayoclinic.org/spanish_patient_consumer_web.xml

  5. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8) - Mayo Clinic

    Jacksonville, Florida: 24-009952; Rochester, Minnesota: 24-009952; Scottsdale/Phoenix, Arizona: 24-009952. NCT ID: NCT06395519. Sponsor Protocol Number: ETX ...

  6. Publications - S. Vincent Rajkumar, M.D. - Mayo Clinic

    Retreatment of multiple myeloma with previously refractory drugs. Blood Adv. 2024 Dec 24; 8(24):6321-6328. View PubMed; Rajkumar SV, Mateos MV, Schaeffer M, Lin ...

  7. Clinical trials - Oncology (Medical)

    Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients ...

  8. https://www.mayoclinic.org/chinese_patient_consumer_web.xml

  9. https://www.mayoclinic.org/spanish_condition_consolidated_concepts.xml

  10. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...